12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Ambrx Biopharma (NYSE:AMAM) shares increased by 9.3% to $0.57 during Monday’s after-market session. This security traded at…
Milestone Pharmaceuticals Q3 EPS $(0.34), Same YoY
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.34) per share. This is unchanged from the same period last year.
Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial Of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session At AHA Scientific Sessions 2022; Says Trial Met Primary Endpoint
Trial met its primary endpoint, with 64.3% of patients receiving etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001)
Median time to
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
Gainers
Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case.
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
Gainers
Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.
Recap: Milestone Pharmaceuticals Q2 Earnings
Milestone Pharmaceuticals (NASDAQ:MIST) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:15 PM.
Here's what investors need to know about the announcement.
Piper Sandler Upgrades Milestone Pharmaceuticals to Overweight, Raises Price Target to $10
Piper Sandler analyst Edward Tenthoff upgrades Milestone Pharmaceuticals (NASDAQ:MIST) from Neutral to Overweight and raises the price target from $8 to $10.
Milestone Pharmaceuticals Q4 EPS $(0.40) Down From $(0.23) YoY
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.40) per share. This is a 73.91 percent decrease over losses of $(0.23) per share from the same period last year.